Duration of chemotherapy for metastatic breast cancer: A systematic review and meta-analysis of randomized clinical trials

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2144-2149

  Gennari, Alessandra ^a,b,c,d,e,f   Stockler, Martin ^a,b,c,d,e,f   Puntoni, Matteo ^a,b,c,d,e,f   Sormani, Mariapia ^a,b,c,d,e,f   Nanni, Oriana ^a,b,c,d,e,f   Amadori, Dino ^a,b,c,d,e,f   Wilcken, Nicholas ^a,b,c,d,e,f   D'Amico, Mauro ^a,b,c,d,e,f   DeCensi, Andrea ^a,b,c,d,e,f   Bruzzi, Paolo ^a,b,c,d,e,f  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUOXYMESTERONE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COCHRANE LIBRARY; EMBASE; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MEDICAL ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79957936823     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.5374     Document Type: Article

References (24)

1. Chia SK, Speers CH, D'yachkova Y, et al: The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973-979, 2007 (Pubitemid 47312861)
2. Gennari A, Conte P, Rosso R, et al: Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer 15:1742-1750, 2005 (Pubitemid 41437440)
3. Andre F, Slimane K, Bachelot T, et al: Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 22:3302-3308, 2004 (Pubitemid 41103686)
4. Dawood S, Broglio K, Gonzalez-Angulo AM, et al: Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26:4891-4898, 2008
5. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington, PA, National Comprehensive Cancer Network, 2010, version 2
6. Stockler MR, Wilcken NJC, Coates AS: Chemotherapy for advanced breast cancer: How long should it continue? Breast Cancer Res Treat 81:S49-S52, 2003 (suppl 1)
7. Coates AS, Byrne M, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer: Intermittent versus continuous chemotherapy for breast cancer. N Engl J Med 317:1490-1495, 1987 (Pubitemid 17160543)
8. Harris AL, Cantwell BM, Carmichael J, et al: Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335:186-190, 1990
9. Muss HB, Case LD, Richards F II, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: The Piedmont Oncology Association. N Engl J Med 325:1342-1348, 1991
10. Ejlertsen B, Pfeiffer P, Pedersen D, et al: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A:527-531, 1993 (Pubitemid 23036300)
11. Gregory RK, Powles TJ, Chang JC, et al: A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33:2194-2197, 1997 (Pubitemid 28123409)
12. Falkson G, Gelman RS, Pandya KJ, et al: Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with breast cancer in complete remission following induction treatment. J Clin Oncol 16:1669-1676, 1998 (Pubitemid 28234708)
13. French Epirubicin Study Group: Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose intensity and duration of treatment. J Clin Oncol 18:3115-3124, 2000
14. Nooij MA, de Haes JCJM, Beex LVAM, et al: Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: Clinical outcomes and oncologists' preferences. Eur J Cancer 39:614-621, 2003 (Pubitemid 36287373)
15. Gennari A, Amadori D, De Lena M, et al: Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24:3912-3917, 2006
16. Mayordomo Ji, Baena JM, Cirera P, et al: Final results of a randomised trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. J Clin Oncol 27:41s, 2009 (abstr 1001)
17. Alba E, Ruiz-Borrego M, Margelí M, et al: Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 122:169-176, 2010
18. Liberati A, Alman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions. Ann Intern Med 151:W65-W94, 2009
19. Tierney JF, Stewart LA, Ghersi D, et al: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16, 2007
20. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1. The Cochrane Collaboration, 2008, pp 243-296. http:// www.cochrane-handbook.org
21. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003 (Pubitemid 37088507)
22. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
23. Egger M, Smith GD, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997 (Pubitemid 27387172)
24. Geels P, Eisenhauer E, Bezjak A, et al: Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395-2405, 2000 (Pubitemid 30415826)